HCG (Human Chorionic Gonadotropin) vs Pasireotide
Overview
HCG (Human Chorionic Gonadotropin) and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares HCG (Human Chorionic Gonadotropin) and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| HCG (Human Chorionic Gonadotropin) | Pasireotide | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 250-500 IU | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | multiple weekly | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Testosterone support, fertility, testicular health | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Possible estrogen increase, injection site reactions | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. HCG (Human Chorionic Gonadotropin) is categorised under Hormonal, while Pasireotide falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. HCG (Human Chorionic Gonadotropin): not FDA-approved; treated as a research compound. Pasireotide: FDA-approved.
Dosing. HCG (Human Chorionic Gonadotropin) is typically dosed at 250-500 IU (multiple weekly). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking HCG (Human Chorionic Gonadotropin) and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between HCG (Human Chorionic Gonadotropin) and Pasireotide?
- HCG (Human Chorionic Gonadotropin) and Pasireotide are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. HCG (Human Chorionic Gonadotropin) is not FDA-approved; generally classified as a research compound, whereas Pasireotide is FDA-approved for one or more indications.
- What is HCG (Human Chorionic Gonadotropin) used for?
- Testosterone production support.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take HCG (Human Chorionic Gonadotropin) and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking HCG (Human Chorionic Gonadotropin) and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is HCG (Human Chorionic Gonadotropin) or Pasireotide FDA-approved?
- HCG (Human Chorionic Gonadotropin) is not FDA-approved; generally classified as a research compound. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- HCG (Human Chorionic Gonadotropin) — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references